On Nov. 18, 2020, RELIEF THERAPEUTICS announced the appointment of Syneos Healthﾮ, a leading global clinical research organization (CRO), to run the European clinical trial in severe COVID-19 induced lung injury, as well as future trials in other indications to be conducted in Europe.

Relief also selected AMRI, a global contract development and manufacturing organization (CDMO), who will provide aseptic fill/finish manufacturing of RLF-100TM at their Glasgow, UK, facility.